Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $59,660 COP
Change Today 0.00 / 0.00%
Volume 0.0
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
SIX Swiss Ex
London
Sao Paulo
Bogota
As of 4:01 PM 09/26/14 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Snapshot

Open
--
Previous Close
$59,660
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
6.2B
EX-Date
08/5/15
P/E TM
--
Dividend
$1.12
Dividend Yield
3.96%
Current Stock Chart for PFIZER INC (PFE)

pfizer inc (PFE) Details

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

78,300 Employees
Last Reported Date: 02/27/15
Founded in 1849

pfizer inc (PFE) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.3M
President of Worldwide Research & Development
Total Annual Compensation: $1.2M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $1.2M
Group President of Global Established Pharma ...
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

pfizer inc (PFE) Key Developments

Pfizer and Synthon Enter into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

Pfizer Inc. and Synthon announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS). Under the terms of the agreement, Pfizer will have exclusive rights to commercialize both dosage formulations of Synthon's glatiramer acetate in the United States. Synthon is responsible for the clinical development, manufacture and supply of glatiramer acetate.

Pfizer Mulls Acquisitions

Pfizer Inc. (NYSE:PFE) is eyeing acquisition targets and has "sufficient courage" to pursue a company takeover, the Financial Times reports, citing comments from Ian Read, Chief Executive Officer of Pfizer, said.

Pfizer Inc. Announces Consolidated Financial Results for the Second Quarter and Six Months of 2015; Provides Earnings Guidance for the Full Year 2015

Pfizer Inc. announced consolidated financial results for the second quarter and six months of 2015. For the quarter, the company reported revenue of $11.853 million against $12.773 million a year ago. Adjusted income was $3.525 million against $3.769 million a year ago. Adjusted diluted EPS was $0.56 against $0.58 a year ago. Reported net income was $2.626 million or $0.42 per diluted share against $2.912 million or $0.45 per diluted share a year ago. Reported revenues decreased $920 million, or 7%, which reflects operational growth of $125 million, or 1%, more than offset by the unfavorable impact of foreign exchange of $1.0 billion, or 8%. Excluding the impact of foreign exchange, adjusted diluted EPS increased by approximately 6%. For the six months, the company reported revenue of $22.717 million against $24.126 million a year ago. Adjusted income was $6.721 million against $7.434 million a year ago. Adjusted diluted EPS was $1.07 against $1.15 a year ago. Reported net income was $5.002 million or $0.80 per diluted share against $5.241 million or $0.81 per diluted share a year ago. For the year of 2015, the company now expects adjusted revenues in a range of $45 to $46 billion as compared to $44 to $46 billion expected earlier; effective tax rate is expected to be approximately 25.0%; Diluted EPS is expected to be in a range of $1.38 to $1.47 as compared to $1.32 to $1.47 expected earlier; and adjusted diluted EPS is expected to be in a range of $2.01 to $2.07 as compared to $1.95 to $2.05 expected earlier.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:CB $59,660.00 COP 0.00

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $174.80 USD -0.79
Gilead Sciences Inc $118.87 USD -0.73
Johnson & Johnson $99.80 USD -0.22
Nestle SA SFr.73.75 CHF +0.20
Procter & Gamble Co/The $75.91 USD -0.49
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 25.7x
Price/Sales 4.6x
Price/Book 3.3x
Price/Cash Flow 17.6x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.